ArticleOncology letters2025
Identification of a cuproptosis‑related prognostic biomarker and therapeutic target in ovarian cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aging at the Crossroads of Cuproptosis and Ferroptosis: From Molecular Pathways to Age-Related Pathologies and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Cuproptosis: a novel therapeutic mechanism in lung cancer.Cancer cell international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OV) constitutes a significant hazard to the health of women and has low survival and high recurrence rates. Cuproptosis is a newly reported form of copper-dependent regulatory cell death. The present study identified cuproptosis-related long non-coding (lnc)RNAs in OV, highlighting their potential application as prognostic biomarkers and therapeutic targets. The RNA-sequencing data and clinical records of patients with OV were sourced from The Cancer Genome Atlas. Cuproptosis-related lncRNAs were filtered for their prognostic value using univariate and multivariate Cox regression, and least absolute shrinkage selection operator regression. Then, a risk model was formulated using these cuproptosis-related lncRNAs based on correlation coefficients. The risk model was calculated using the following formula: Risk = (0.687927022 × RP11-552D4.1) - (0.659783022 × AP001372.2) - (0.652465319 × RP11-505K9.1) - (1.627006889 × LINC00996). The predictive potential and clinical values of this risk model were identified through survival status, Kaplan-Meier survival curves, immune function, receiver operating characteristic curves, calibration curves, C-index and principal component analysis. Subsequently, the effects of LINC00996 (the lncRNA with the highest correlation coefficient in the risk model) on proliferation, metastasis and sensitivity to cuproptosis were assessed in OV cells. Finally, intracellular location of LINC00996 and the relative regulatory mechanism were predicted. In conclusion, the present study constructed a prognostic risk model based on lncRNAs associated with cuproptosis in OV, which can stratify risk and predict prognosis, and explored the regulatory mechanism of LINC00996 in cuproptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.